Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'

Br J Clin Pharmacol. 2017 Jun;83(6):1357-1358. doi: 10.1111/bcp.13276. Epub 2017 Apr 3.

Authors

Elisabet Størset^{1

2}, Kristine Hole³, Karsten Midtvedt¹, Stein Bergan^{4

5}, Espen Molden^{3

4}, Anders Åsberg^{1

4}

Affiliations

¹ Department of Transplant Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
² Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
³ Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
⁴ Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
⁵ Department of Pharmacology, Oslo University Hospital Rikshospitalet, Oslo, Norway.

No abstract available

Keywords: 4β-hydroxycholesterol; CYP3A; bodyweight; kidney transplantation; tacrolimus.

Publication types

Letter
Comment

MeSH terms

Body Weight
Cytochrome P-450 CYP3A / genetics*
Genotype
Humans
Hydroxycholesterols
Immunosuppressive Agents
Kidney Transplantation
Tacrolimus*

Substances

Hydroxycholesterols
Immunosuppressive Agents
Cytochrome P-450 CYP3A
Tacrolimus